Skip to content

Moxibustion for the Treatment of Lymphedema in women who have Breast Cancer Surgery

Moxibustion as an Adjuvant Therapy in control of Lymphedema in women mastectomized for breast cancer: a randomized study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9wkgdxp
Enrollment
Unknown
Registered
2023-04-18
Start date
2021-08-02
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Lymphedema

Interventions

This is a randomized clinical study, with parallel, prospective and monocentric treatments. Carried out with 28 women who survived breast cancer and had lymphedema after unilateral mastectomy. Partici
E02.190
E02.190.044.588

Sponsors

Faculdade de Enfermagem Nossa Senhora das Graças da Universidade de Pernambuco
Lead Sponsor
Sociedade Pernambucana de Combate ao Câncer
Collaborator

Eligibility

Sex/Gender
Female
Age
30 Years to No maximum

Inclusion criteria

Inclusion criteria: Women aged 30 years or older, diagnosed with breast cancer and who underwent unilateral mastectomy at least six months ago, allowing comparison between the two limbs; Undergoing neoadjuvant and/or adjuvant radiotherapy and chemotherapy, which may increase the risk of developing lymphedema; Proof of lymphedema through perimetry of the affected arm =3 cm than that of the contralateral arm.

Exclusion criteria

Exclusion criteria: Diseases related to the vascular system, coagulopathies, skin infections or any condition that contraindicates moxibustion; Limb skin trauma, ulceration or skin disease, as such conditions can hinder venous and lymphatic return; Patients who have breathing problems (allergy to subtle smells), since they can be aggravated by the technique; Women who are receiving other treatments for lymphedema other than those established by the service, in order to guarantee homogeneity in the therapeutic protocol and allow comparisons; Previous contact with any modality of moxibustion, as it will make it impossible for the participant to be blinded; Pregnancy, as there is controversy regarding the safety of moxa in early pregnancy.

Design outcomes

Primary

MeasureTime frame
Expected outcome 1: An Effective Index for Upper-Limb Lymphedema value equal to or greater than 20% is expected.;Outcome found 1: An Effective Index for Upper-Limb Lymphedema of 23.0% was observed in the intervention group, and only 5.3% in the control group, with a value of p=0.016 (derived from the Man Whitney U test).

Secondary

MeasureTime frame
Secondary outcomes were not expected.

Countries

Brazil

Contacts

Public ContactLaura Moraes

Universidade de Pernambuco

laura.moraes@upe.br+55 81 998284199

Outcome results

None listed

Source: REBEC (via WHO ICTRP)